Title: TXA Quick Review (submitted by Kortney Morrell, PharmD)<br/>Author: Ashley Martinelli<br/><a href='mailto:1912'>[Click to email author]</a><hr/><table border="1" cellpadding="0" cellspacing="0" style="width:621px;" width="621">
        <tbody>
                <tr>
                        <td style="width:169px;height:105px;">
                                <p align="center">
                                        <strong>Mechanism of Action </strong></p>
                        </td>
                        <td style="width:452px;height:105px;">
                                <p>
                                        Tranexamic Acid (TXA) is an antifibrinolytic agent that is a competitive inhibitor of plasminogen activation, and a non-competitive inhibitor of plasmin </p>
                                <p>
                                        Inhibits the breakdown of fibrin mesh allowing clot formation</p>
                                <ul>
                                        <li>
                                                Vial Concentration: 1000mg/10 mL </li>
                                </ul>
                        </td>
                </tr>
                <tr>
                        <td rowspan="2" style="width:169px;height:93px;">
                                <p align="center">
                                        <strong>When is it Indicated? </strong></p>
                        </td>
                        <td style="width:452px;height:93px;">
                                <p>
                                        <strong>Epistaxis/Oral Bleeds/Fistula Bleeds</strong></p>
                                <ul>
                                        <li>
                                                Local application of injectable form of TXA </li>
                                        <li>
                                                <u>Dose</u>: Gauze soaked with 500 mg (5 mL) applied topically to the site of bleeding </li>
                                </ul>
                        </td>
                </tr>
                <tr>
                        <td style="width:452px;height:96px;">
                                <p>
                                        <strong>Trauma</strong></p>
                                <ul>
                                        <li>
                                                <u>Criteria for use:</u> Significant hemorrhage or significant risk of hemorrhage in adult trauma patients (SBP <90 mmHg and/or HR >110 bpm) </li>
                                        <li>
                                                <u>Dose:</u> 1g in 100 mL 0.9% NaCl infused over 10 minutes followed by 1g in 100 mL 0.9% NaCl over 8 hours </li>
                                </ul>
                        </td>
                </tr>
                <tr>
                        <td style="width:169px;height:133px;">
                                <p align="center">
                                        <strong>Adverse Reactions </strong></p>
                        </td>
                        <td style="width:452px;height:133px;">
                                <ul>
                                        <li>
                                                Generally well tolerated</li>
                                        <li>
                                                GI Disturbances: nausea, vomiting, diarrhea </li>
                                        <li>
                                                Thrombotic Events </li>
                                        <li>
                                                Hypersensitivity reactions: anaphylaxis and anaphylactoid reactions </li>
                                        <li>
                                                Hypotension following rapid injection (maximum rate is 100 mg/minute) </li>
                                </ul>
                        </td>
                </tr>
        </tbody>
</table>
<p>
         </p>